Kamada slumps on reticence to explain 'positive signal' in AAT trial
This article was originally published in Scrip
Executive Summary
Kamada of Israel believes that despite missing the primary endpoint in a Phase II/III trial, positive secondary endpoint data and results from a recently initiated US Phase II trial will be enough to persuade regulators to approve its inhaled alpha-1 antitrypsin (AAT) therapy for the treatment of alpha-1 antitrypsin deficiency (AATD or inherited emphysema).